🚀 VC round data is live in beta, check it out!
Alector Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alector and similar public comparables like Circio Holding, SAB Bio, Dishman Carbogen Amics, Flerie and more.
Alector Overview
About Alector
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Founded
2013
HQ
Employees
244
Website
Sectors
Financials (LTM)
EV
$46M
Alector Financials
Alector reported last 12-month revenue of $25M and negative EBITDA of ($157M).
In the same LTM period, Alector generated $25M in gross profit, ($157M) in EBITDA losses, and had net loss of ($137M).
Revenue (LTM)
Alector P&L
In the most recent fiscal year, Alector reported revenue of $21M and EBITDA of ($146M).
Alector expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $25M | XXX | $21M | XXX | XXX | XXX |
| Gross Profit | $25M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($157M) | XXX | ($146M) | XXX | XXX | XXX |
| EBITDA Margin | (619%) | XXX | (695%) | XXX | XXX | XXX |
| EBIT Margin | (588%) | XXX | (741%) | XXX | XXX | XXX |
| Net Profit | ($137M) | XXX | ($143M) | XXX | XXX | XXX |
| Net Margin | (542%) | XXX | (679%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alector Stock Performance
Alector has current market cap of $266M, and enterprise value of $46M.
Market Cap Evolution
Alector's stock price is $2.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $46M | $266M | -0.4% | XXX | XXX | XXX | $-1.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlector Valuation Multiples
Alector trades at 1.8x EV/Revenue multiple, and (0.3x) EV/EBITDA.
EV / Revenue (LTM)
Alector Financial Valuation Multiples
As of April 10, 2026, Alector has market cap of $266M and EV of $46M.
Equity research analysts estimate Alector's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alector has a P/E ratio of (1.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $266M | XXX | $266M | XXX | XXX | XXX |
| EV (current) | $46M | XXX | $46M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | (0.3x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | — | XXX | XXX | XXX |
| P/E | (1.9x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alector Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alector Margins & Growth Rates
Alector's revenue in the last 12 month grew by 22%.
Alector's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.
Alector's rule of 40 is (401%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alector's rule of X is (289%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alector Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 22% | XXX | 74% | XXX | XXX | XXX |
| EBITDA Margin | (619%) | XXX | (695%) | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (401%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (289%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 198% | XXX | 257% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 478% | XXX | 585% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 841% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alector Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Circio Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| SAB Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Flerie | XXX | XXX | XXX | XXX | XXX | XXX |
| ProKidney | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alector M&A Activity
Alector acquired XXX companies to date.
Last acquisition by Alector was on XXXXXXXX, XXXXX. Alector acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alector
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlector Investment Activity
Alector invested in XXX companies to date.
Alector made its latest investment on XXXXXXXX, XXXXX. Alector invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alector
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alector
| When was Alector founded? | Alector was founded in 2013. |
| Where is Alector headquartered? | Alector is headquartered in United States. |
| How many employees does Alector have? | As of today, Alector has over 244 employees. |
| Who is the CEO of Alector? | Alector's CEO is Arnon Rosenthal. |
| Is Alector publicly listed? | Yes, Alector is a public company listed on Nasdaq. |
| What is the stock symbol of Alector? | Alector trades under ALEC ticker. |
| When did Alector go public? | Alector went public in 2019. |
| Who are competitors of Alector? | Alector main competitors are Circio Holding, SAB Bio, Dishman Carbogen Amics, Flerie. |
| What is the current market cap of Alector? | Alector's current market cap is $266M. |
| What is the current revenue of Alector? | Alector's last 12 months revenue is $25M. |
| What is the current revenue growth of Alector? | Alector revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Alector? | Current revenue multiple of Alector is 1.8x. |
| Is Alector profitable? | No, Alector is not profitable. |
| What is the current EBITDA of Alector? | Alector has negative EBITDA and is not profitable. |
| What is Alector's EBITDA margin? | Alector's last 12 months EBITDA margin is (619%). |
| What is the current EV/EBITDA multiple of Alector? | Current EBITDA multiple of Alector is (0.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.